19 - 21 October, 2026
The Westin Miyako KyotoKyoto, JapanKey Sessions
Taichi Kuramochi
Beyond Conventional Antibodies: Innovative Strategies in Antibody Engineering and Drug Discovery
Chugai Pharmaceutical, Japan
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference Day 1 - JT (Japan Time, GMT+09:00)
keyboard_arrow_leftSearch & Filter
search
Streams
Main Conference Day 1 - JT (Japan Time, GMT+09:00)
search
Streams
Showing 1 of 1 Streams
Registration
08:30 - 09:00
Morning Registration
Showing 1 of 1 Streams
Keynote Presentations
09:00 - 09:30
Beyond Conventional Antibodies: Innovative Strategies in Antibody Engineering and Drug Discovery
- Switch-Ig technology designed to exploit the unique features of the tumour microenvironment
- An antibody engineering platform integrating AI and laboratory automation
- A first-in-class multispecific antibody for celiac disease targeting the gluten peptide/HLA complex
- Taichi Kuramochi - Head of Biologics Discovery, Chugai Pharmaceutical, Japan
Showing 1 of 1 Streams
Bridging the Gap between Engineering and Clinical Rationality
Morning Break
Showing 1 of 1 Streams
Break
10:30 - 11:00
Morning Break & Networking
Showing 1 of 1 Streams
Bridging the Gap between Engineering and Clinical Rationality
11:00 - 11:30
Early-Stage Developability Assessment for Bispecific Antibody Lead Optimization and Selection
BsAbs offer strong therapeutic potential, but complex formats can introduce developability risks, such as aggregation, non-specific binding, and instability. This session introduces early-stage developability assessment that evaluates PK (self-association, non-specific binding, FcRn affinity, and serum stability), biophysical properties, stability, and immunogenicity, highlighting how modality-driven assessment can guide lead optimization, reduce downstream risks, and accelerate bsAb R&D.
- Lei Guo, Ph.D. - Senior Director, CRO Services, Wuxi Biologics, China
Showing 1 of 1 Streams
The Digital & Next-Gen Frontier: Navigating AI and Emerging Modalities
12:00 - 12:30
EMLy™: Powering Smarter, Faster, and Scalable AI-Guided Biologics Development
- Alfred Lim, PhD - Director of Lab Research, Etcembly Ltd., UK
Lunch
Showing 1 of 1 Streams
Break
12:30 - 13:30
Lunch Break & Networking
Showing 1 of 1 Streams
The Digital & Next-Gen Frontier: Navigating AI and Emerging Modalities
13:30 - 14:00
Marriage of single-cell and cell-free technologies for rapid and comprehensive generation of high-performance antibodies
- Shoji Ohuchi, Ph.D., MBA - Co-CEO, CSO and CTO, iBody Inc., Japan
14:00 - 14:30
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan
- Kaori Mukai - Principal Scientist, Sanofi, USA
14:30 - 15:00
Advancing Next-Generation Antibody Drug Discovery through Chiome’s DoppeLib Platform and Integrated Drug Discovery Partnerships
- Kiyotoshi Mori - Head of Research Division, Chiome Bioscience Inc., Japan
Afternoon Break
Showing 1 of 1 Streams
Break
15:00 - 15:30
Afternoon Break & Networking
Showing 1 of 1 Streams
The Digital & Next-Gen Frontier: Navigating AI and Emerging Modalities
15:30 - 16:00
Multispecific antibodies targeting ion channel- based multiprotein complexes in cancer
- Annarosa Arcangeli - Full Professor, University of Florence, Italy
16:30 - 17:00
Logical design of biparatopic antibodies based on stoichiometry engineering
- Hiroki Akiba - Senior Lecturer, Kyoto University
17:00 - 17:30
Physics aware machine learning methods for modeling dynamics, expansion of chemical space and the design of intracellular biologics
- Philip Kim, PhD - Professor, University of Toronto & CTO and Co-Founder, Fable Therapeutics, Canada
END OF DAY 1
Showing 1 of 1 Streams
Break
17:30 - 17:35
END OF MAIN CONFERENCE DAY 1
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams